Copertina

Clinical Experience of Risankizumab in Patients With a History of Erythrodermic Psoriasis

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Che‐Chia Hsu, Chang‐Yu Hsieh, Tsen‐Fang Tsai
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Experimental Dermatology
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Acquired diffuse palmoplantar erythema with keratoderma in Chinese patients with pustular psoriasis: A predictor for IL36 receptor antagonist c.115+6T>C mutation?
di: Francis Li‐Tien Hsu, et al.
Pubblicazione: (2024)

Correction to “Safety and Effectiveness of Ixekizumab in Japanese Patients with Psoriasis Vulgaris, Psoriatic Arthritis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis: Post‐marketing Surveillance”
Pubblicazione: (2025)

Dose Modulation Strategies in Psoriatic Patients: Real‐Life Pilot Comparison Between Risankizumab and Guselkumab up to 12 Months After Dose Spacing
di: Luca Mastorino, et al.
Pubblicazione: (2025)

Exploring the Impact of Guselkumab and Risankizumab on Psoriasis in HIV‐Positive Patients: Insights From Four Italian Centers
di: V. Maione, et al.
Pubblicazione: (2025)

Active Switch From a Single Dose of Bimekizumab to Risankizumab in Psoriasis: A Pilot Study
di: Kaori Nakajima, et al.
Pubblicazione: (2025)

Nail Involvement Among Psoriasis Patients: A Comparative Retrospective Cohort Analysis of 2888 Egyptian Patients
di: Nermeen Ibrahim Bedair, et al.
Pubblicazione: (2025)

IL ‐ 17A Inhibitors Therapy Affect Oral Fungal and Bacterial Microbiome in Psoriasis
di: Shiqi Wang, et al.
Pubblicazione: (2026)

The Impacts of Seasonal Factors on Psoriasis
di: Jundan Yang, et al.
Pubblicazione: (2025)

Insulin‐like growth factor 2 mRNA‐binding protein 3 enhanced melanoma migration through regulation of AKT1 and RELA expression
di: Yi‐Shuan Sheen, et al.
Pubblicazione: (2024)

Complications and Laboratory Test Findings Among Patients With Generalized Pustular Psoriasis: A Retrospective Chart Review Study
di: Ryuhei Okuyama, et al.
Pubblicazione: (2026)

Use of Baricitinib in Patients With TIF1 ‐γ Positive Dermatomyositis Following a COVID ‐19 Infection
di: Guan‐Kai Lai, et al.
Pubblicazione: (2026)

Mapping the Causal Landscape of Psoriasis: A Systematic Mendelian Randomization Evidence Synthesis and Development of the MR ‐ PsO Atlas Platform
di: Jin‐Yu Lu, et al.
Pubblicazione: (2026)

Biologic Efficacy by BMI in Moderate‐To‐Severe Psoriasis: A Real‐World Cohort Study
di: Xin Shen, et al.
Pubblicazione: (2026)

Genital Psoriasis in Asians: Impact on Quality of Life and Sexual Health
di: Kim Yao Ong, et al.
Pubblicazione: (2025)

Extension of Secukinumab and Ixekizumab Dose for Moderate‐To‐Severe Psoriasis in Low Disease Activity Intervals
di: Caiyu Wang, et al.
Pubblicazione: (2025)

Macrophages in Psoriasis: From Functional Heterogeneity to Metabolic Reprogramming and Novel Therapeutics
di: Qianzi Liu, et al.
Pubblicazione: (2026)

Population‐Specific HLA Profiles in Generalised Pustular Psoriasis in Sarawak, Malaysia
di: Ingrid Pao Lin Ting, et al.
Pubblicazione: (2026)

Evaluating Psoriasis Severity Using the Neutrophil‐to‐Lymphocyte Ratio and Platelet‐to‐Lymphocyte Ratio: A Systematic Review and Meta‐Analysis
di: Yi‐Hsuan Shen, et al.
Pubblicazione: (2026)

DUSP6 Regulates Skin Inflammation, Parakeratosis and Disease Severity in a Murine Model of Psoriasis
di: Teresina Laragione, et al.
Pubblicazione: (2026)

Efficacy and Safety of Risankizumab in Psoriatic Patients With a History of Malignancy: Real‐World Evidence From a Multicentre Spanish Study
di: Javier Mataix Díaz, et al.
Pubblicazione: (2025)

Increased Abnormal Erythrocytes Caused by Spleen Filtration Deficiency Provide a Hypoxic Environment for the Occurrence of Psoriasis
di: Ya Zhao, et al.
Pubblicazione: (2024)

Cold Stress Activates ACSL1 + Macrophages in a Fatty Acid‐Dependent Manner to Exacerbate Psoriasis
di: Ce Shuai, et al.
Pubblicazione: (2026)

Updated Psoriasis Prevalence and Risk Factors in the United States—Insights From the 2023 NHIS
di: Priya Engel, et al.
Pubblicazione: (2025)

Reduced EZH2 Expression in Circulating CD8 ‐Positive T Cells and Monocytes in Psoriasis
di: Toyoki Yamamoto, et al.
Pubblicazione: (2026)

Contribution of Phenotypic Age Acceleration and Body Mass Index to Psoriasis Risk in US Adults
di: Yun‐Ni Lin, et al.
Pubblicazione: (2026)

High‐throughput proteomic analysis of chronic inflammatory skin diseases: Psoriasis and atopic dermatitis
di: Tanel Traks, et al.
Pubblicazione: (2024)

Lesional Psoriasis is Associated With Alterations in the Stratum Corneum Ceramide Profile and Concomitant Decreases in Barrier Function
di: Jannik Rousel, et al.
Pubblicazione: (2024)

Distinct Gut Microbiome Signatures of Complete Responders to Omalizumab in Chronic Spontaneous Urticaria
di: Yung‐Tsu Cho, et al.
Pubblicazione: (2026)

A Case of Erythrodermic Psoriasis Successfully Treated With Ixekizumab Combined With Low‐Dose Methotrexate to Ensure Sustained Clearance: A Case Report
di: Jennifer Lavina Ngo, et al.
Pubblicazione: (2025)

Identification of Polyamine Metabolism‐Related Biomarkers in Psoriasis: A Study Based on Transcriptomics and Single‐Cell Sequencing
di: Li Zhang, et al.
Pubblicazione: (2026)

Erythrodermic dermatomyositis with anti‐TIF1‐γ antibodies
di: Ke‐yun Tang, et al.
Pubblicazione: (2024)

Efficacy of Risankizumab in Patients with Suboptimal Response or Failure to Ustekinumab: A Multicenter Retrospective Study in Spain
di: Jorge Magdaleno-Tapial, et al.
Pubblicazione: (2024)

A Systematic Review of Mendelian Pyoderma Gangrenosum: Clinical and Genetic Characteristics in 120 Published Patients
di: Leyla Norouzi‐Barough, et al.
Pubblicazione: (2025)

Real‐World Experience of 3‐Year Treatment With Dupilumab: Significant Decrease in Circulating Neutrophils and Eosinophils in Japanese Patients With Atopic Dermatitis
di: Hideyuki Nakajima, et al.
Pubblicazione: (2024)

Analysis of the Dynamics of Clinical Parameters and Serum Angiogenic Factors in Systemic Sclerosis Patients Undergoing Tocilizumab Treatment
di: Yuichiro Segawa, et al.
Pubblicazione: (2026)

Effective Management of Recalcitrant Hailey–Hailey Disease With Risankizumab
di: Joy Justice, et al.
Pubblicazione: (2026)

Tildrakizumab for Psoriasis in Patients With Current or Prior Malignancy: Methodological Considerations and Clinical Implications
di: Yaqing Zhao, et al.
Pubblicazione: (2026)

Erythrodermic Ulcerated Form of Mycosis Fungoides Demonstrating Long‐Term Response to Brentuximab Vedotin
di: Himino Ashida, et al.
Pubblicazione: (2026)

Sustained Remission of Pediatric Bowel‐Associated Dermatosis‐Arthritis Syndrome With Risankizumab
di: Kylie E. Peake, et al.
Pubblicazione: (2026)

Clinical Efficacy and Safety of Intramuscular Injections of Autologous Total IgG in Patients With Chronic Spontaneous Urticaria: An Open‐Label Prospective Pilot Trial
di: Young‐Min Ye, et al.
Pubblicazione: (2026)